Stocks · Health care · Biological Products, (No Diagnostic Substances)

PALISADE BIO, INC.

PALI Clue Score57
United States Fiscal year ends December CIK 0001357459 Results filed 10 Aug 2026

What the insiders did Net buying

By person

20 insiders · 45 transactions
0.6×

J.D. Finley holds only 0.6 times base salary in stock. $356.33K of shares against $575.00K in salary for 2025.

Salary from the company's own proxy. The shares are what J.D. Finley last reported holding, valued at $1.46, the price Common Stock was last bought or sold at on the open market here, on 2 Oct 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Robert Baltera Jr.
Director
$250.18K (6)
—
+$250.18K
461,904
$674.38K
—
John David Finley
CEO CFO
$101.50K (12)
$310.16K (2) scheduled
−$208.66K
2,147,914
$3.14M
—
Mitchell Lawrence Jones
See Remarks
—
$110.02K (2)
−$110.02K
1,683,757
$2.46M
—
Richard J Daly
Chief Executive Officer
$70.00K (5)
—
+$70.00K
23,312
$34.04K
—
Donald Allen Williams
Director
$68.27K (7)
—
+$68.27K
1,623,294
$2.37M
+81,065%
Robert J. Trenschel
Director
$42.30K (5)
$192.00 (1)
+$42.11K
315,399
$460.48K
—
Thomas Hallam
Chief Executive Officer
$36.74K (3)
—
+$36.74K
57,592
$84.08K
—
Jones Jonathan Brian Lloyd
Chief Financial Officer
$30.00K (1)
—
+$30.00K
7,859
$11.47K
+226.9%
Michael John Dawson
Chief Medical Officer
$17.09K (1)
—
+$17.09K
15,000
$21.90K
—
Julien E. Capers
See Remarks
—
—
—
787,300
$1.15M
—
Binxian Wei
Director
—
—
—
613,355
$895.50K
+30,667,650%
Emil Chuang
Director
—
—
—
612,500
$894.25K
—
Jordan Michael Zwick
Director
—
—
—
336,904
$491.88K
—
Sandford D Smith
Director
—
—
—
219,916
$321.08K
+2,581%
Stanley Westreich
Director
—
—
—
143,281
$209.19K
+14.9%
William Clyde Oldaker
Director
—
—
—
33,763
$49.29K
+123.0%
Cristina Csimma
Director
—
—
—
12,862
$18.78K
+20,645%
Stephanie Diaz
Director
—
—
—
12,800
$18.69K
—
James R Neal
Director
—
—
—
10,920
$15.94K
—
Robert Curtis McRae
Chief Operating Officer
—
—
—
625
$912.50
+160.4%

No percentages here. This company's share count has moved by a factor of 39.6 over the window, from 4,396,646 to 174,270,558 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.